Physician profile
Jim M John
NPI 1841404233
$2,628.68
in general payments reported to CMS, 2019-2025
20 companies · $740 in 2025
The $740 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $330 · 2021: $35.56 · 2022: $300 · 2023: $526 · 2024: $397 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $489.43 | 2022-2025 | Avvigo Guidance System, Watchman Access System, Rotapro |
| Abbott Laboratories | $484.08 | 2023-2025 | Dragonfly Opstar, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $225.41 | 2022-2025 | |
| Abiomed | $188.97 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $159.88 | 2019-2023 | Xarelto |
| Angiodynamics, INC. | $151.14 | 2025 | Alphavac |
| Astrazeneca Pharmaceuticals LP | $128.37 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $125.79 | 2022 | |
| Amgen INC. | $110.02 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $61.94 | 2020 | |
| Kestra Medical Technology Services, INC. | $42.61 | 2024 | Assure Wcd |
| Siemens Medical Solutions USA, INC. | $42.30 | 2023-2024 | Acuson Origin Diagnostic Ultrasound System, Acuson Sequoia Diagnostic Ultrasound System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.07 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $36.20 | 2024-2025 | Verquvo, Capvaxive |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $24.67 | 2024 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $18.79 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.13 | 2022 | |
| Heartflow, INC. | $16.64 | 2023 | Ffrct |
| Amarin Pharma, INC. | $16.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.